Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
SGHT affiliate submitted a Form 144 notice to sell securities. The filing lists 12,733 shares associated with restricted stock vesting and compensation, and reports 13,761 shares were sold in the past three months (04/06/2026). The broker-dealer listed is Fidelity Brokerage Services LLC.
SGHT filer submitted a Form 144 notice reporting proposed sale of 6,902 shares of Common Stock tied to Restricted Stock Vesting.
The filing lists shares outstanding 54,409,942 as of 07/02/2026 and discloses prior sales of 7,231 shares on 04/06/2026 with a reported value of $25,632.43. The filing identifies Fidelity Brokerage Services LLC as the broker.
SGHT filed a Form 144 notice reporting proposed or planned sales of Common stock, including 24,184 shares associated with a 06/30/2026 restricted stock vesting event. The filing lists prior open-market sales of 25,874 shares on 04/02/2026 and 12,728 shares on 05/18/2026 with corresponding dollar amounts.
SGHT notice reports 2,829 shares of Common Stock listed under “Securities To Be Sold” tied to Restricted Stock Vesting with an event dated 06/30/2026. The filer entry lists a broker Fidelity Brokerage Services LLC and a filing reference date 07/01/2026.
SGHT submitted a Form 144 notice for the proposed sale of 28,684 shares of Common Stock tied to restricted stock vesting on 06/30/2026. The filing also records a prior sale by Paul Badawi of 29,244 shares on 04/01/2026 for $108,082.90. Shares outstanding were 54,409,942 as of 07/01/2026.
Sight Sciences director and 10% owner Staffan Encrantz reported an open-market purchase of 14,100 shares of Common Stock at a weighted average price of $4.879 per share. After this trade, he directly holds 1,434,283 shares, including 28,261 restricted stock units subject to vesting as previously reported.
He also reports indirect interests in 5,086,920 shares held by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust, where he is a trustee, and 632,456 shares held by Allegro Investment Fund, L.P. He disclaims beneficial ownership of Allegro’s shares and of the trust and fund holdings beyond any pecuniary interest.
Fountain Tamara reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences director Tamara Fountain received an equity grant in the form of restricted stock units. She was awarded 28,261 RSUs on June 4, 2026 under the company’s Non-Employee Director Compensation Program, representing approximately $130,000 of common stock based on the closing price that day.
The RSUs vest on the earlier of June 4, 2027 and the company’s 2027 annual meeting of stockholders, subject to her continued board service. Following this grant, she holds 109,650 shares and units in total, including 81,389 shares of common stock and 28,261 unvested RSUs.
Encrantz Staffan reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences director Staffan Encrantz received an equity award in the form of restricted stock units (RSUs). He was granted 28,261 RSUs under the company’s Non-Employee Director Compensation Program, with the number of units based on approximately $130,000 of common stock at the closing price on June 4, 2026.
The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, contingent on his continued board service. Following this grant, his direct holdings include 1,391,922 shares of common stock plus the 28,261 RSUs, totaling 1,420,183 shares. Additional indirect positions are reported through the 1997 Staffan and Margareta Encrantz Revocable Trust and Allegro Investment Fund, L.P., with beneficial ownership of those shares disclaimed as described in the footnotes.
Burbach Gerhard F reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences, Inc. reported that director Gerhard F. Burbach received a grant of 28,261 restricted stock units (RSUs) under the company’s Non-Employee Director Compensation Program. The award equals approximately $130,000 of common stock based on the closing price on June 4, 2026.
The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, if he continues serving as a director through that date. Following this grant, he directly holds a total of 123,207 common shares and RSUs, including 44,922 shares of common stock and RSUs from current and prior awards.
Zurbay Donald reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences director Donald Zurbay received a grant of 28,261 restricted stock units (RSUs) under the company’s Non-Employee Director Compensation Program. The award value is approximately $130,000, based on the closing price of the common stock on June 4, 2026.
The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, as long as Zurbay continues serving on the board through that date. After this grant, he has a total reported position of 193,613 shares and rights, including common shares, unvested RSUs, and stock options exercisable within 60 days.